FDA Greenlights Oral Version of Wegovy for Weight Management

The U.S. Food and Drug Administration (FDA) has granted approval for an oral formulation of the weight management medication Wegovy, as announced by its manufacturer, Novo Nordisk.

This marks a significant milestone as it is the first oral weight-loss drug to receive such endorsement from the regulatory agency, heralding a new chapter in the realm of weight-loss treatments.

According to Novo Nordisk, the Danish pharmaceutical company behind Wegovy, the once-daily pill offers a convenient alternative to the injectable version while delivering comparable weight reduction results.

This development follows the FDA’s prior approval of Wegovy specifically for weight loss, while similar medications like Ozempic have been primarily sanctioned for managing Type 2 diabetes, despite their weight-loss benefits.

In a recent update, the company reported that participants in Wegovy’s clinical trials experienced an average weight loss of 16.6%, with approximately one-third of the nearly 1,300 individuals shedding 20% or more of their body weight.

The oral version of Wegovy is anticipated to hit the U.S. market in early January 2026, offering patients a practical and effective method for weight loss.

Mike Doustdar, the CEO of Novo Nordisk, emphasized that this new pill will provide individuals with a straightforward option to achieve weight loss comparable to the original injection.

This innovation could significantly enhance Novo Nordisk’s revenue prospects following a tough year marked by declining shares and profit warnings.

The company faces stiff competition in the weight-loss sector from rivals such as Eli Lilly, but the introduction of this oral Wegovy could strengthen its market position.

Following the announcement, Novo Nordisk’s stock saw an uptick of nearly 10% in after-hours trading in New York.